Fig. 2From: Type II CRISPR/Cas9 approach in the oncological therapyCas9 structure. The alpha-helical lobe and the nuclease lobe composed by, RuvC and HNH domain. The D10A and the H840A mutations in these last two domains cause the loss of ability to perform a DSB making only a single nick per strand. These particular Cas9 are commonly called NickasesBack to article page